AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio [Yahoo! Finance]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Yahoo! Finance
The studies did not meet their primary endpoint of showing a statistically significant improvement in the change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score compared to the placebo group at week 6. Truist says due to the failure, Bristol Myers Squibb & Co's (NYSE: BMY ) Cobenfy (xanomeline and trospium chloride, KarXT) is poised to have less commercial competition. The analyst also adds that the update will likely raise questions about strategy in neuroscience for AbbVie, which was highlighted during their third-quarter earnings call The analyst, with a Buy rating and $215 price target, is still positive on AbbVie's growth prospects particularly from their immunology I&I franchise. Emraclidine was part of AbbVie's acquisition of Cerevel last year, which also included Tavapadon, which recently reported positive Phase 3 results in Parkinson's disease. The trial met its primary endpoint – patients treated with tavapadon in both dose groups exp
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Why this major drugmaker no longer has an ‘IT department' [Yahoo! Finance]Yahoo! Finance
- Is Bristol-Myers Squibb Company (BMY) Among The Top Dividend Contenders Right Now? [Yahoo! Finance]Yahoo! Finance
- Why this major drugmaker no longer has an ‘IT department' [Fortune]Fortune
- Bristol-Myers Squibb (NYSE: BMY) was upgraded by analysts at Daiwa Capital Markets from a "neutral" rating to an "outperform" rating.MarketBeat
- Bristol-Myers Squibb (NYSE: BMY) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.MarketBeat
BMY
Earnings
- 10/31/24 - Beat
BMY
Sec Filings
- 11/5/24 - Form 4
- 11/5/24 - Form 4
- 11/5/24 - Form 4
- BMY's page on the SEC website